Mantle Cell Lymphoma

Two Treatment Strategies Transform the Mantle Cell Lymphoma Paradigm

September 28, 2020

In an interview with Targeted Oncology, Peter Martin, MD, discusses the current mantle cell lymphoma treatment landscape and the future of the field.

Exploring Targeted and CAR T-Cell Therapies on the Horizon for MCL

September 25, 2020

Michael Wang, MD, discusses potential upcoming treatment options for patients with mantle cell lymphoma, including targeted therapies and chimeric antigen receptor T cells.

Ibrutinib and Venetoclax Under Investigation as First-Line Combo in MCL

September 14, 2020

The combination of ibrutinib and venetoclax will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.

FDA Grants Fast Track and Orphan Drug Designations to VLS-101 for Treatment of MCL

August 31, 2020

The FDA granted a Fast Track and Orphan Drug designation to VLS-101 for the treatment of patients with mantle cell lymphoma.

A 66-Year-Old Woman With Mantle Cell Lymphoma

August 28, 2020

Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.

Investigational Therapy in Mantle Cell Lymphoma: KTE-X19 CAR T-Cell Therapy

August 24, 2020

Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.

Exploring Unmet Needs and BTK Inhibitors in the MCL Population

August 20, 2020

Nilanjan Ghosh, MD, discusses the current unmet needs in mantle cell lymphoma and how Bruton’s tyrosine kinase inhibitors are being looked at to fill that need for patients with high-risk disease in the first line.

Expert Reviews Treatment Landscape for Patients With Mantle Cell Lymphoma

August 19, 2020

Lori A. Leslie, MD, discusses the current treatment options for patients with mantle cell lymphoma.

Meta-Analysis Highlights Commonly Mutated Genes in Mantle Cell Lymphoma

August 17, 2020

The frequency of mutations in patients with mantle cell lymphoma has a tendency to increase at clinical turning points like disease relapse and progression compared with at the time of diagnosis, according to a systemic review and meta-analysis.

Temsirolimus Plus R-CHOP Most Feasible of Chemotherapy Combinations in R/R Mantle Cell Lymphoma

August 12, 2020

Combining temsirolimus with a chemotherapy regimen as treatment of patients with relapsed or refractory mantle cell lymphoma is feasible, according to the phase 1b T3 clinical trial.